Report with market evolution powered by AI- The global hepatitis b and c diagnostics market size is estimated to grow by USD ...

Over the past few years, Abbott Laboratories' (NYSE: ABT) business has been a bit of a roller coaster. The pandemic disrupted its medical device business, but it was later able to smooth out those ...

Abbott Laboratories' diabetes care segment recently added new products to its lineup. It should remain one of the company's key growth drivers over the long run. There are other good reasons to ...

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report), with a price target of $133.00. The company’s shares ...

In a report released today, Patrick Wood from Morgan Stanley maintained a Hold rating on Abbott Laboratories (ABT – Research Report), with a price target of $107.00. Patrick Wood has given his ...

Fintel reports that on September 19, 2024, Piper Sandler initiated coverage of Abbott Laboratories (NYSE:ABT) with a Overweight recommendation. As of August 26, 2024, the average one-year price ...

The projected fair value for Abbott Laboratories is US$132 based on 2 Stage Free Cash Flow to Equity With US$116 share price, Abbott Laboratories appears to be trading close to its estimated fair ...

Abbott Laboratories (ABT) stock saw a modest uptick, ending the day at $116.43 which represents a slight increase of $2.57 or 2.26% from the prior close of $113.86. The stock opened at $114.46 and ...

Shares of Abbott Laboratories ABT sank 0.37% to $116.40 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.54% to 5,626.02 ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...